NASDAQ$SERA

Sera Prognostics Inc-A · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported third quarter 2022 financial results, showing increased revenue and operating expenses.

Sera Prognostics reported increased revenue for the third quarter of 2022, reaching $87,000 compared to $23,000 in the same period of 2021. However, the company experienced a net loss of $10.7 million, slightly higher than the $9.9 million loss in the third quarter of the previous year. The company's cash, cash equivalents, and available-for-sale securities totaled approximately $111.2 million as of September 30, 2022.

  • Revenue increased to $87,000 in Q3 2022 from $23,000 in Q3 2021.
  • Operating expenses rose to $11.3 million, up from $9.5 million in the same quarter last year.
  • Net loss for the quarter was $10.7 million, compared to $9.9 million in the prior year.
  • Cash, cash equivalents, and available-for-sale securities amounted to $111.2 million as of September 30, 2022.

Headline financials

Total Revenue

$87K

Previous: $23K+278.3%
EPS (adj)

-$0.35

Previous: -$0.39+10.3%
Capital Expenditures

-$598K

Previous: -$555K-7.7%
Free Cash Flow

-$11.3M

Previous: -$10.4M-8.6%
Net Income

-$10.7M

Previous: -$9.86M-8.7%
Operating Income

-$11.2M

Previous: -$9.44M-18.5%
Gross Profit

$29K

Previous: $13K+123.1%
Cash & Equivalents

$38.8M

Previous: $82.5M-52.9%
Total Assets

$117M

Previous: $154M-24.2%
Stock-Based Comp

$1.28M

Previous: $914K+39.8%

Revenue & EPS history

Sera Prognostics · Revenue · Quarterly

$87K

Q3 2022+278.3%vs Q3 2021
Beat estimate in 3 of 15 quarters(20%)
ActualEstimate

Forward guidance

Sera Prognostics anticipates revenue contributions from integrated healthcare systems as early as Q4 2022, with more significant impacts expected in 2023 and beyond. The company also anticipates the public release of validation data for preeclampsia risk prediction by the end of 2022 and expects an interim look analysis from the PRIME study in 2023.

Tailwinds

  • Integrated healthcare systems starting to show success.
  • Additional contracts with new self-insured employer plans executed.
  • Clinical utility data anticipated to be made public in 2023.
  • Validation of preeclampsia risk prediction expected by year-end 2022.
  • PRIME study enrollment continuing to enable interim look analysis in 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-1.9%

Avg return

Earnings day

-3.5%

Avg return

5 days after

-3.3%

Avg return

30 days after

36%

8 / 22 earnings

Positive

+14.3%

Q3 2022

Best reaction

-11.7%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.7%-8.0%+18.1%
Q4 2025-7.7%+6.3%+20.4%
Q3 2025+1.7%+8.5%+19.0%
Q1 2025-11.7%-2.1%-35.4%
Q4 2024-5.1%-2.2%-17.9%
Q3 2024-0.3%-2.7%-3.9%
Q2 2024+0.0%-1.2%-2.2%
Q1 2024+3.3%-4.0%-13.6%
Q4 2023+3.4%+1.1%+7.7%
Q3 2023-3.2%-6.4%+130.9%
Q2 2023+0.8%-10.1%-39.9%
Q1 2023-0.8%-2.8%-13.0%
Q4 2022-10.0%-9.5%-22.3%
Q3 2022+14.3%+11.1%-4.0%
Q2 2022-4.1%-6.3%-27.3%
Q1 2022-7.6%-17.1%-32.7%
Q4 2021+3.6%+0.3%-39.3%
Q3 2021+0.3%-0.8%-8.2%
Q3 2020+0.3%-0.8%-8.2%
Q2 2021-4.8%-9.9%+0.0%
Q1 2021-4.8%-9.9%+0.0%
Q4 2020-4.8%-9.9%+0.0%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro